Lipocine, Verity in License Agreement for TLANDO® Franchise in U.S. and Canada

 

• Lipocine to receive $11 million license fee
• Up to $259 million in development and commercial sales milestones
• Tiered royalties on net sales of licensed products up to 18%
• Commercialization of TLANDO transitions to Verity Pharma effective Feb.1 2024
• Lipocine retains all rights for territories outside the United States and Canada, and all non-TRT rights globally

https://www.prnewswire.com/news-releases/lipocine-and-verity-pharma-enter-into-license-agreement-for-tlando-franchise-in-the-us-and-canada-302037718.html